DBV Technologies S.A. (DBVT) vs Iambic Therapeutics (IAM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Iambic Therapeutics is the larger company by market cap ($621.4 million vs $566.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DBVT | IAM |
|---|---|---|
| Share price | $9.02 | $13.11 |
| Market cap | $566.82M | $621.42M |
| 1-day change | -4.25% | -8.06% |
| YTD return | -52.95% | — |
| 1-year return | -34.40% | — |
| 5-year return | +50.33% | — |
| EPS (TTM) | $-3.00 | $-2.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.64M | — |
| Revenue growth (YoY) | +35.77% | — |
| Net income (latest FY) | $-146.95M | — |
| Operating margin | -2609.23% | — |
| Net margin | -2607.29% | — |
| 52-week high | $26.19 | $25.00 |
| 52-week low | $8.63 | $9.60 |
| Distance from 52-week high | -65.55% | -47.56% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +305.10% | +107.86% |
| Average volume | 352.88K | 714.92K |
| Shares outstanding | 62.84M | 47.40M |
| Employees | 179 | 171 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About DBV Technologies S.A.
DBVT stock →DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 179 employees
About Iambic Therapeutics
IAM stock →Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 171 employees
DBVT vs IAM FAQ
Which is bigger, DBV Technologies S.A. or Iambic Therapeutics?
Iambic Therapeutics (IAM) is larger, with a market capitalization of $621.42M compared with $566.82M for DBV Technologies S.A. (DBVT).
Are DBV Technologies S.A. and Iambic Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.